Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...

Major depressive disorder with seasonal patterns, also known as seasonal affective disorder, causes symptoms similar to ...

Johnson & Johnson has added to the opioid kappa blues. Months after Neumora reported a phase 3 flop, J&J has stopped ...

Menopause can worsen symptoms of bipolar disorder. In rare cases, it may trigger bipolar disorder. Menopause is a factor when ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Mind Medicine ($MNMD) announced its Q4 financials and indicated it is making strides in developing innovative treatments for ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...